Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin vs Insulin+Glucagon Meal Challenge in T1D
NCT04712266Phase 1Completed
- Sponsor
- Abvance Therapeutics
- Start
- Sep 2020
- Primary completion
- Dec 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ABV100 in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Abvance Therapeutics. Primary endpoints: Hypoglycemic excursions and Hyperglycemic excursions. Started Sep 2020; status: completed.
02
Drugs
ABV100
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT04712266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04712266.